MedMind ’s Post

🚀 Advancing Small Molecule Drug Discovery with AI 🧬 Gilead's recent partnership with Genesis Therapeutics highlights the exciting future of AI-driven drug discovery. As AI technologies evolve, the potential for identifying and developing novel small molecule therapies grows exponentially. At Viltis, we believe that this integration of AI into life sciences is key to solving some of the most complex challenges in drug development. With our deep expertise in clinical operations, regulatory compliance, and scientific consulting, Viltis is uniquely positioned to support pharmaceutical and biotech companies as they explore new frontiers in drug development. Whether it’s guiding clinical trials, ensuring FDA compliance, or offering scientific expertise in pharmaceutical R&D, we’re here to help our clients bring breakthrough therapies to market faster and more efficiently. 🌍 Let’s collaborate to drive innovation in drug discovery and transform patient outcomes! https://lnkd.in/g6FCW2zU #DrugDiscovery #AI #Pharma #LifeSciences #RegulatoryCompliance #ClinicalTrials

Thoughts on this? >> Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

Thoughts on this? >> Gilead partners with AI startup Genesis Therapeutics to make small molecule drugs >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #healthcare #pharmaceutical #productmarketing

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gjiU7ZRh It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gs_bUHEB 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

“Herantis achieved significant milestones in 2023; a successful first-in-human trial with HER-096 and strengthening of the financial position. We are excited that Phase 1a trial met its primary and secondary endpoints: good safety profile, favourable pharmacokinetic profile, and efficient penetration to central nervous system after subcutaneous administration. This provides a solid basis for further clinical development of the highly promising HER-096 as disease-modifying therapy for Parkinson’s disease. We also signed a term sheet with EIC Fund, the investment arm of the EIC, for up to EUR 15 million in direct equity investments. In December, despite of the very challenging environment for biotech companies, we were delighted to close a financing round and welcome EIC Fund as a new investor. After a successful 2023, we are enthusiastic to advance HER-096 into the next stage of development,” said Antti Vuolanto, CEO of Herantis Pharma Plc. #HerantisPharma #ParkinsonDisease #Biotech #CDNF #HER096 #DiseaseModifying #drugdevelopment #pharma 

Genesis Therapeutics Lands Gilead Sciences Deal for AI Drug Discovery Genesis Therapeutics has secured a collaboration with Gilead Sciences, marking its third major pharma partnership. Under the agreement, Gilead will pay $35 million upfront for AI-based drug discovery on three undisclosed targets and has the option to add more targets for a set fee. Gilead gains development and commercialization rights for any resulting compounds, with Genesis eligible for milestone payments and royalties. CEO Evan Feinberg, Ph.D., highlighted that their AI platform tackles data challenges in drug discovery. Previously, Genesis partnered with Genentech and Eli Lilly and Company, and last year it raised $200 million in Series B funding from investors including Andreessen Horowitz, Fidelity Management And Research Company, BlackRock, and NVIDEA’s nVentures. At GlenFlow, we’re excited about these advancements in AI-driven drug discovery. They inspire us as we work on more diverse applications for our ScaleFlow AI Suite. Moreover, our medical device startup, OxyDial, is led by the same fuel of constant enhancements and improving patients' lives globally. Read more: https://lnkd.in/e-hZkhtB #HealthcareAI #MedTech #AIFunding #FutureMedicine #VentureCapital #PersonalizedCare #DrugDiscovery #HealthInnovation

💰 Recent biotech funding and start-up activities by BiopharmIQ by Amp 𝐏𝐨𝐬𝐭-𝐈𝐏𝐎/𝐏𝐮𝐛𝐥𝐢𝐜 𝐅𝐮𝐧𝐝𝐢𝐧𝐠 Cartesian Therapeutics - Raised $130M in post-IPO funding to advance its programs and general corporate goals. Bionano - Announced a $30M public offering, including $10M upfront and $20M through warrants linked to the achievement of clinical milestones. e-therapeutics PLC - Completed £28.9M of post-IPO funding to advance several of its developments, including GalOmic™. InspireMD - Utilised $17.9M of Series H warrants following the successful results of the C-GUARDIAN study. Checkpoint Therapeutics Inc - Raised $12M in a private placement to support working capital and corporate purposes. 𝗣𝗿𝗶𝘃𝗮𝘁𝗲 𝗙𝘂𝗻𝗱𝗶𝗻𝗴 Myricx Bio - Raised £90M in Series A round to develop its innovative ADC platform. Circle Pharma, Inc. - Raised $54.1M in private equity, strengthening its financial position. Kanvas Biosciences - Raised an additional $12.5M to advance its microbiome-based immuno-oncology business. AnBogen Therapeutics - Completed a $7.3M Series A+ financing round to further advance its Phase 2 clinical trial of ABT-301. Granza Bio (YC W24) - Raised $7.14M in a seed round, backed by Felicis and Refactor, to advance its oncology and autoimmune disease pipeline. Source: https://lnkd.in/g46ZDXuq #biotech #biopharma

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact

Could Your Investments Save Lives? Why Not Consider Biopharmaceuticals? 🧪🚀 City Therapeutics, a radiant star in the biopharmaceutical galaxy that specializes in RNA interference-based medicine, has recently announced a monumental raise of $135M in Series A funding. Based out of Cambridge, MA, this revolutionary company is making waves by innovatively and scientifically pushing boundaries. Their latest triumph illustrates their tremendous growth and potential impact on global health. A story worth reading here 👉 https://lnkd.in/gD3GErD6 It's time to Ignite Corporate Innovation! AI solutions and automation are instrumental tools for corporate growth. Don't miss your chance to join our network of 160K+ corporate decision-makers, investors, and innovative founders dedicated to transforming innovation strategies into successful ventures! Raise the bar for your corporation. Let’s discuss how: https://lnkd.in/gH39iDY3 💪 #CityTherapeutics #RNAInterference #Biopharma #SeriesAFunding #InvestmentOpportunity #InnovationStrategies #CorporateGrowth #AutomationRevolution #CambridgeMAStartups #GlobalHealthImpact